Clinical Trial Update: A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk [Phase 2, Phase 3]

View source ↗

Summary

A pharmacodynamic study comparing a personalized P2Y12 inhibition strategy against ticagrelor to reduce ischemic and bleeding risk in acute coronary syndrome pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Percutaneous Coronary Intervention

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Ottawa Heart Institute Research Corporation | Conditions: Acute Coronary Syndrome, Percutaneous Coronary Intervention | Phase 2, Phase 3 | Status: COMPLETED